Tags

Type your tag names separated by a space and hit enter

Hematological findings and complications of COVID-19.
Am J Hematol. 2020 07; 95(7):834-847.AJ

Abstract

COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.

Authors+Show Affiliations

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Hematology and Thrombosis Center, Tenon University Hospital, Sorbonne University, INSERM U938, Sorbonne University, Paris, France. Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Hematology Laboratory-Blood Bank, Aretaieio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Hematology and Thrombosis Center, Tenon University Hospital, Sorbonne University, INSERM U938, Sorbonne University, Paris, France. Research Group "Cancer, Haemostasis and Angiogenesis," INSERM U938, Centre de Recherche Saint-Antoine, Institut Universitaire de Cancérologie, Faculty of Medicine, Sorbonne University, Paris, France.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Pub Type(s)

Journal Article
Systematic Review

Language

eng

PubMed ID

32282949

Citation

Terpos, Evangelos, et al. "Hematological Findings and Complications of COVID-19." American Journal of Hematology, vol. 95, no. 7, 2020, pp. 834-847.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-847.
Terpos, E., Ntanasis-Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T. N., Politou, M., Psaltopoulou, T., Gerotziafas, G., & Dimopoulos, M. A. (2020). Hematological findings and complications of COVID-19. American Journal of Hematology, 95(7), 834-847. https://doi.org/10.1002/ajh.25829
Terpos E, et al. Hematological Findings and Complications of COVID-19. Am J Hematol. 2020;95(7):834-847. PubMed PMID: 32282949.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hematological findings and complications of COVID-19. AU - Terpos,Evangelos, AU - Ntanasis-Stathopoulos,Ioannis, AU - Elalamy,Ismail, AU - Kastritis,Efstathios, AU - Sergentanis,Theodoros N, AU - Politou,Marianna, AU - Psaltopoulou,Theodora, AU - Gerotziafas,Grigoris, AU - Dimopoulos,Meletios A, Y1 - 2020/05/23/ PY - 2020/04/07/received PY - 2020/04/08/accepted PY - 2020/4/14/pubmed PY - 2020/4/14/medline PY - 2020/4/14/entrez SP - 834 EP - 847 JF - American journal of hematology JO - Am. J. Hematol. VL - 95 IS - 7 N2 - COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted. SN - 1096-8652 UR - https://www.unboundmedicine.com/medline/citation/32282949/full_citation L2 - https://doi.org/10.1002/ajh.25829 DB - PRIME DP - Unbound Medicine ER -